Details

Autor(en) / Beteiligte

• Garcia-Samaniego, J

Titel

Should We Treat Chronic Hepatitis C in HIV with Peginterferon Alpha 2a or 2b?

Ist Teil von

• AIDS reviews, 2010-01, Vol.12 (1)

Erscheinungsjahr

2010

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Since 2001, the recommended therapy for patients with chronic hepatitis C virus (HCV) infection is a combination of pegylated interferon alpha (PEG-IFNa) plus ribavirin. The two commercially available preparations of PEG-IFNa (2a and 2b) differ in pegylation sites, molecular weight, and structure, resulting in significant differences in pharmacokinetic and pharmacodynamic properties. The registration trials of both PEG-IFNa for the treatment of chronic hepatitis C conducted almost 10 years ago yielded sustained virologic response (SVR) rates of 54% for PEG-IFNa 2b (Manns, et al. Lancet. 2001; 358:958-65) and 56-63% for PEG-IFNa 2a respectively (Fried, et al. N Engl J Med. 2002; 347:975-82; Hadziyannis, et al. Ann Intern Med. 2004; 140:346-55). Accordingly, and in the absence of a head-to-head comparative trial, both PEG-IFNs were considered as equipotent.